Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

2.8%

1 terminated/withdrawn out of 36 trials

Success Rate

96.0%

+9.5% vs industry average

Late-Stage Pipeline

42%

15 trials in Phase 3/4

Results Transparency

8%

2 of 24 completed trials have results

Key Signals

3 recruiting2 with results

Enrollment Performance

Analytics

Phase 3
8(29.6%)
Phase 1
8(29.6%)
Phase 4
7(25.9%)
Phase 2
3(11.1%)
N/A
1(3.7%)
27Total
Phase 3(8)
Phase 1(8)
Phase 4(7)
Phase 2(3)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (36)

Showing 20 of 36 trials
NCT07087912Phase 4Recruiting

Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases

Role: collaborator

NCT06842173Phase 1Recruiting

Safety and Immunogenicity of the Monovalent Influenza Vaccine A (H5N8) (Inactivated, Fragmented and Adjuvanted) in Adults and Older Adults

Role: lead

NCT06891950Phase 3Recruiting

Butantan-DV Vaccine in Elderly Populations (DEN-04-IB)

Role: lead

NCT06973772Phase 3Not Yet Recruiting

Trial to Evaluate the Immunogenicity and Safety of the Co-administration of Live Attenuated Dengue and Chikungunya Vaccines Compared to Separate Administration in Adults Aged 18 to 59 Years.

Role: lead

NCT05710224Phase 2Completed

Clinical Bridging Study Between V181 (Dengue Quadrivalent Vaccine rDENVΔ30 [Live, Attenuated]) to Butantan Dengue Vaccine (Butantan - DV) in Healthy Adults 18 to 50 Years of Age in Brazil (V181 - 002)

Role: lead

NCT05779020Phase 3Completed

Immunogenicity and Safety of Butantan Quadrivalent Influenza Vaccine (Split Virion, Inactivated) in Infants and Children .

Role: lead

NCT03927131Phase 3Completed

Safety and Immunogenicity of the Butantan Quadrivalent Influenza Vaccine

Role: lead

NCT05354024Phase 2Completed

Phase II/III Randomized Clinical Trial of Booster Dose of COVID-19 (Recombinant, Inactivated) Vaccine

Role: lead

NCT04355338Completed

Assessment of Incidence of SARS-CoV-2 Infection and COVID-19 in Brazil (AVISA)

Role: lead

NCT04650399Phase 3Completed

A Multicenter Study to Evaluate Safety and Immunogenicity of a Live-attenuated Chikungunya Vaccine in Adolescents

Role: lead

NCT04747821Phase 4Completed

An Effectiveness Study of the Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine

Role: lead

NCT04408014Completed

Seroepidemiological Study of SARS-CoV-2 (COVID-19) Infection in Population Subgroups in the State of São Paulo

Role: lead

NCT02406729Phase 3Active Not Recruiting

Phase III Trial to Evaluate Efficacy and Safety of a Tetravalent Dengue Vaccine

Role: lead

NCT04456595Phase 3Completed

Clinical Trial of Efficacy and Safety of Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine in Healthcare Professionals

Role: lead

NCT03777163Phase 4Completed

Safety and Immunogenicity of the Butantan Institute Influenza Vaccine Compared to Sanofi Pasteur Influenza Vaccine

Role: lead

NCT04993209Phase 1Completed

Clinical Trial of the COVID-19 Vaccine (Recombinant, Inactivated) in Brazil

Role: lead

NCT04845048Completed

Active Pharmacovigilance Study of Adsorbed COVID-19 (Inactivated) Vaccine

Role: lead

NCT01693380Phase 4Completed

Effectiveness Assessment of Vaccinating Schoolchildren Against Influenza

Role: lead

NCT05225285Phase 3Unknown

Efficacy, Immunogenicity and Safety of Inactivated Vaccine (Coronavac) Against SARS-COV2 in Children and Adolescents

Role: collaborator

NCT04789356Phase 4Unknown

Effectiveness of the Adsorbed Vaccine COVID-19 (Coronavac) Among Education and Public Safety Workers With Risk Factors for Severity

Role: collaborator